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Abstract
Objective: To investigate the modulating effects of current smoking on adherence and responses to pulmonary rehabilitation (PR) in patients 
with chronic obstructive pulmonary disease (COPD). Methods: In a prospective study, 18 ex-smokers and 23 current smokers (GOLD stages 
II-III) were enrolled in a 12-week multidisciplinary, supervised PR program. The patients were assessed clinically and as to subjective variables 
(dyspnea and health-related quality of life) and objective variables (body composition, pulmonary function and 6-min walking distance). The 
degree of nicotine dependence in current smokers was assessed by the Fagerström test. Program completion defined PR “adherence”. 
Results: There was a significant association between current smoking and non-adherence to PR with 30.4% vs. 11.1% and odds ratio=2.9 
(1.6-4.1; p<0.01). However, the current smokers who completed the program (n=16) had a similar absentee rate to the ex-smokers, as well 
as similar gains in the subjective (quality of life) and objective (walked distance) items. Additionally, there was a significant reduction in daily 
cigarette consumption and in the degree of nicotine dependence in current smokers (p<0.05). Conclusions: Although current smoking is 
negatively related to PR adherence, COPD smokers who complete the PR can have similar gains in functionality and quality of life compared 
to ex-smokers. Moreover, PR may be related to decreased nicotine dependence, even without a formal smoking withdrawal program.
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Resumo
Objetivo: Investigar o possível efeito modulador do tabagismo atual na aderência e nos efeitos da reabilitação pulmonar (RP) em pacientes 
com doença pulmonar obstrutiva crônica (DPOC). Métodos: Em um estudo prospectivo, 18 pacientes ex-tabagistas e 23 tabagistas atuais 
(GOLD estádios II-IV) foram incluídos num programa multidisciplinar de RP com duração de 12 semanas. Os pacientes foram submetidos 
à avaliação clínica e à de variáveis subjetivas (dispneia e qualidade de vida) e objetivas (composição corporal, função pulmonar e teste da 
caminhada de 6 minutos). Nos pacientes tabagistas, obteve-se o nível de dependência da nicotina pela escala de Fagerström. A interrupção 
da RP antes do término previsto foi considerada indicativa de não aderência ao programa. Resultados: A proporção de pacientes não-
aderentes à RP foi maior nos tabagistas do que nos ex-tabagistas (30,4% vs 11,1%, respectivamente; razão de chance=2,9 (1,6-4,1); 
p<0,01). Entretanto, os tabagistas atuais que completaram o programa (n=16) apresentaram taxa de absenteísmo à RP similar ao observado 
nos ex-tabagistas, assim como ganhos equivalentes nas respostas subjetivas (qualidade de vida) e objetivas (distância caminhada). 
Adicionalmente, houve redução significante no número de cigarros consumidos diariamente e no grau de dependência da nicotina nos 
tabagistas atuais (p<0,05). Conclusões: Embora o tabagismo atual reduza a aderência à RP, pacientes tabagistas com DPOC que completam 
tais programas apresentam ganhos funcionais e na qualidade de vida equivalentes aos observados nos ex-tabagistas. A RP, mesmo sem um 
programa estruturado de cessação do tabagismo, pode associar-se com redução, ao menos a curto prazo, da dependência da nicotina.
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Introduction 
Pulmonary rehabilitation (PR) has been an important ad-
junctive treatment for chronic obstructive pulmonary disease 
(COPD), optimizing the level of independence and exercise 
tolerance with subsequent improvement in quality of life1,2. 
Although PR has a multidisciplinary character, several rando-
mized controlled trials have shown that structured physical 
training is crucial for clinical and functional improvement, 
with prognostic repercussions3.
Unfortunately, the capacity of health services to offer such 
programs for all patients with indication of PR is known to be 
lower than the real demand1,2,4. One of the common eligibility 
criteria for a PR program is the exclusion of current smokers1,3, 
based on the assumptions that such patients would be less 
adherent to PR5,6 and that the potential gains would be lower 
than those observed in non-smokers because of the harmful 
effects of smoking on pulmonary function7 and the skeletal 
muscle8. Additionally, it is known that smokers are less likely to 
initiate and maintain regular physical activity9,10. However, the 
available evidence to substantiate the concept that PR should 
not be offered to current smokers is scarce, as admitted recen-
tly2. In fact, some randomized studies accepted smokers in 
their program11,12, and the influence of current smoking on the 
main clinical and functional outcomes of PR in COPD remains 
controversial.
Therefore, the main purpose of this study was to assess 
adherence to the PR and its subjective effects (dyspnea and 
health-related quality of life) and objective effects (body com-
position, pulmonary function and exercise capacity) on current 
smokers and ex-smokers with COPD. The main hypothesis of 
the study was that current smoking did not influence negati-
vely on adherence and on the gains provided by the PR in this 
population. 
Methods 
Sample 
We assessed a consecutive convenience sample of 41 pa-
tients of both sexes with a diagnosis of COPD (GOLD stages 
II-IV) 13 referred by the institution’s outpatient clinic and pri-
vate pulmonology care services. All patients had obstructive 
respiratory disease, typically of moderate to severe intensity 
(FEV1/FVC <0.7 and FEV1 <60% of predicted). The patients 
were divided into: group I (n=18), consisting of ex-smokers 
for at least 6 months and group II (n=23), consisting of cur-
rent smokers. The inclusion criteria were chronic dyspnea 
in activities of daily living (dyspnea score >I according to the 
modified Medical Research Council [MRC] dyspnea scale)4 
and clinical stability, as indicated by the absence of changes in 
the therapeutic regimen or exacerbation of any severity in the 
previous 12 weeks. Exclusion criteria were: presence of motor 
or neurological disorder, indication and/or use of long-term 
home oxygen therapy, pulmonary rehabilitation in the previ-
ous year, chronic use of oral steroids, concomitant diagnosis of 
malignant disease, chronic heart failure, liver disease or neph-
ropathy. This study was approved by the Ethics Committee of 
Faculdade de Medicina do ABC, protocol No. 132/2006, and all 
patients signed an informed consent form. 
Protocol
Before and after PR, the participants underwent a clinical 
and anthropometric assessment, measurement of chronic dys-
pnea scores (modified MRC dyspnea scale)4 and health-related 
quality of life (St. George’s respiratory questionnaire - SGRQ)14, 
assessment of the degree of nicotine dependence (Fagerstrom 
test)15, spirometry, measurement of maximal respiratory 
pressures and the six-minute walking distance (6MWD). All 
questionnaires were administered by the same examiner who 
remained blind to the participants’ smoking history. 
Measurements
Adherence to PR 
Adherence to the PR was defined as the participant’s abil-
ity to complete the proposed program, with at least 80% at-
tendance of sessions16-18. If the participant withdrew from the 
PR before the end of the proposed period, he/she was asked to 
state the reasons for withdrawal. 
Dyspnea scale in daily living
The degree of dyspnea in daily activities was measured 
by the modified MRC dyspnea scale4. In this instrument, “0” 
represents dyspnea during intense exercise and “4”, dyspnea at 
rest. A previously validated Portuguese version of the quality of 
life SGRQ14 was used to assess the participant’s symptoms and 
their influence on daily activities. The SGRQ addresses issues 
related to three components: Symptoms, Activity and Impacts. 
In this instrument, the quality of life is inversely related to the 
score: reductions equal to or greater than 4 points after inter-
vention indicate a significant improvement in quality of life19.
 Scale of nicotine dependence 
The Fagerstrom scale was used in the active smokers to 
verify the degree of nicotine dependence15. This scale has six 
questions about smoking habits and rates the degree of depen-
dency as mild (0-4), moderate (5-7) or severe (8-10).
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Anthropometric measurements 
Body mass (kg) and height (m) were obtained with an an-
thropometric Filizola® scale (Filizola, São Paulo, Brazil). These 
data were used to calculate the body mass index (BMI = weight/
height2, kg/m2). Body fat was also assessed by measuring the 
skinfolds of the right side of the body with a Sanny® skinfold 
caliper (American Medical do Brasil, São Bernardo do Campo, 
Brazil). The same evaluator measured the following skinfolds 
three times: triceps, suprailiac, chest, abdominal and crural. 
The mean value of the measures was considered for analysis. 
Based on this data, the mean density20 and percentage of fat 
and lean body mass20 were calculated.
 Pulmonary function tests 
Spirometry pre- and post-bronchodilator (400 µg of salbu-
tamol via inhalation dosimeter) was performed in the Koko 
system® (Koko spirometry, Louisville, CO, USA), by the same 
technician, using a calibrated pneumotachograph. The crite-
ria for acceptability and reproducibility were those defined by 
the Brazilian Society of Pulmonology and Phthisiology21. The 
forced vital capacity (FVC, L), forced expiratory volume in one 
second of FVC (FEV1, L) and the relationship between them 
were obtained; in the slow maneuvers, the inspiratory capac-
ity (IC, L) was obtained. The values obtained were compared 
to those predicted for the adult Brazilian population22. In this 
study, only the optimal functional values are shown, i.e. after 
the bronchodilator.
Measurements of maximal inspiratory pressure (MIP, 
cmH2O) from residual volume and maximal expiratory pres-
sure (MEP, cmH2O) from the total lung capacity were also car-
ried out. The test was performed with the patient seated, using 
a Newmed® manovacuometer (Newmed, São Paulo, Brazil), 
with measurement of -150/+150 cmH2O. At least three mea-
sures were taken by the same observer, recording the highest 
value obtained as long as it was not the last to be recorded. 
Six-minute walking distance
The 6MWD measures the distance walked in six minutes 
(m) in a 30-meter corridor with standardized encouragement. 
The technical aspects were those recommended by the Ameri-
can Thoracic Society23. During the test, oxyhemoglobin satura-
tion by pulse oximetry (SpO2%) and heart rate (HR bpm) were 
measured (Moriya®, model 1005; Moriya, São Paulo, Brazil). 
Lower limb fatigue and dyspnea were assessed at the end of 
the test using the Borg categorical scale23. 
Interventions
The PR program was carried out in three months, with a fre-
quency of three times per week, lasting 60 minutes each, with a 
total of 36 sessions. In addition to physical training (see below), 
monthly educational lectures were delivered to address aspects 
of the disease, activities of daily living, energy conservation, 
body awareness and nutrition education. The harmful effects 
of smoking and its role in the maintenance of symptoms were 
discussed, but there was no standardized smoking withdrawal 
program or administration of adjuvant drug treatment.
The two groups were submitted jointly to the same physical 
training program, based on the recommendations of the Amer-
ican Thoracic Society1. The program consisted of: (i) warm-up 
followed by 20 minutes of aerobic conditioning on Movement® 
stationary bicycles (Movement Bike vertical BM2800, with 
electromagnetic resistance, Manaus, Brazil), with modulated 
intensity according to individual tolerance (Borg scores for 
dyspnea from 4 to 5)23; (ii) stretching of the muscles to be exer-
cised during the session; (iii) upper and lower limb resistance 
training at 50% of the maximum load reached in a previous 
incremental test and an additional 0.5 kg according to par-
ticipant tolerance; and (iv) cool-off including stretching of the 
muscles exercised during the session. The training was con-
stantly monitored, and supplemental oxygen was used when a 
significant decrease in SpO2 (<90%) was observed.
Statistical analysis 
The minimum sample size (N = 15) for each group was 
calculated assuming a gain of 54m in walking distance as a 
primary outcome24, risk α of 5% and statistical power of 80%. 
Adherence to PR was not used to calculate the sample size be-
cause it is a dichotomous categorical variable (withdrawal or 
not). The data collected were analyzed in a specific program for 
statistical analysis (Statistical Package for Social Sciences™ - 
SPSS, version 13.0).
An initial descriptive analysis was performed to assess the 
distribution of variables and the presence of inconsistencies in 
the database (outliers). The variables were expressed as mean 
and standard deviation or median (variation) according to the 
symmetrical or asymmetrical nature of the distributions (Kol-
mogorov-Smirnov). Unpaired Student t-tests or Mann-Whitney 
tests were performed to compare the groups at baseline as-
sessment. The χ2 test and Fisher’s exact test, when necessary, 
were used to investigate the association between variables. 
Odds ratio for adherence to PR, with its respective confidence 
interval of 95% (CI 95%), was calculated from a contingency 
table. The sign test was used to analyze individual changes in 
the occurrence of dichotomous variables. Two-way repeated 
measures ANOVA was used to compare the groups in the pre- 
and post-PR assessment and any intergroup differences in the 
magnitude of improvement with PR. The probability of type I 
error was set at 5% for all tests (p <0.05).
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Results 
Adherence to PR in current smokers and ex-
smokers
Eighteen ex-smokers and 23 current smokers were as-
sessed. There was a statistically significant relationship 
between current smoking and withdrawal from PR (p <0.05). 
Two (11.1%) of the 18 ex-smokers withdrew from the PR 
program before its completion, whereas 7 (30.4%) of the 23 
current smokers did not complete the program (odds ratio = 
2.9 (1.6-4.1); p <0.01; Table 1). The reasons given for withdra-
wal from the program were similar in both groups: “lack of 
motivation,” “the requirement of frequent attendance” and 
“transportation problems”. However, three patients in the 
current smoker group reported that the contributing factors 
to withdrawal were the references to the harmful effects 
of smoking and to the need to quit to control the disease. 
All patients who completed the program attended at least 
80% of sessions, regardless of smoking history. Additionally, 
there was no significant difference in physiological and sub-
jective baseline variables between the current smokers who 
completed and those who did not complete the PR (p> 0.05; 
data not included).
General characteristics of the sample 
The main demographic, anthropometric and respiratory 
function characteristics of the ex-smokers (group I, n = 16) and 
current smokers (group II, n = 16) who completed the PR are 
presented in Table 1. The distribution of severity, according to 
the GOLD criteria13, was similar between groups I and II: 2/3, 
8/6 and 6/7 for stages II, III and IV, respectively. However, group 
II showed significantly lower inspiratory capacity values, an in-
dex of lung hyperinflation (Table 1)25.
Although not statistically significant, there was a ten-
dency for lower BMI and lean body mass values in group II. 
In fact, the rate of underweight participants and those with 
reduced BMI26 was higher in this group compared to group I 
(9/16 vs. 4/16). The quality of life scores at baseline were signi-
ficantly lower in group II than in group I (p <0.05). It was also 
observed that 81% of participants in group II had moderate 
nicotine dependence and 19%, severe dependence according 
to the Fagerstrom test15. 
Group I
(N= 18)
Group II
(N= 23)
Variables Demographics Pre-PR Post-PR Pre-PR Post-PR
Gender, male/female 9/9 - 13/10 -
Age (yrs)  64.1±8.7 - 63.1±8.3 -
Anthropometric
BMI (kg/m2) 25.8±6.7 27.8±7.3 22.5±6.89 22.6 ± 67
% Lean mass 69.9±8.5 73.8±9.2 † 73.0±11.5 74.9 ± 9.30
Lung function
FVC (%) 66.2±22.8 76.3±25.3 64.3±18.6 67.6 ± 15.8
FEV1 (%) 42.8±15.7 48.0±19.3 45.4±18.1 45.9 ± 17.3
FEV1/FVC 0.46±0.09 0.48±0.11 0.50±0.10 0.50±0.13
IC (%) 81.4±14.5 80.9±13.7 65.4±12.5* 80.1 ± 11.0 †
MIP (cmH2O) 65.0±22.2 77.1±24.3 57.1±24.0 60.3 ± 24.4
MEP (cmH2O) 78.7±26.9 75.0±28.9 71.5±37.2 72.8 ± 26.9
Exercise tolerance
Distance walked  (m) 415±147 495±78 † 427±131 503 ± 113 †
Leg effort score 3 (0-7) 1.5 (0-5) † 2 (0-5) 3 (0-5)
Dyspnea score 4 (0-7) 2.5 (0-5) † 3 (0-5) 2.5 (0-4)
Subjective responses
MRC score 2 (1-4) 2 (1-4) 2 (1-3) 1 (1-3) †
SGRQ 33.5 (21-58) 28.5 (8-45) † 39 (20-62)* 23.5 (5-53) †‡
Non-adherence to PR (%) 11.1% (2) 30.4% (7)
Table 1. Baseline values and objective and subjective responses to pulmonary rehabilitation (PR) in ex-smokers (Group I) and current smokers 
(Group II) with COPD.
Definition of abbreviations: BMI = body mass index; FVC = forced vital capacity; FEV1 = forced expiratory volume in one second; IC = inspiratory capacity; MIP= maximal inspiratory 
pressure; MEP= maximal expiratory pressure; MRC = Medical Research Council; SGRQ = St. George’s Respiratory Questionnaire.
* p<0.05= pre-PR between-group differences; † p<0.05= post-PR within-group differences; ‡ p<0.05= between-group differences in changes induced by PR (repeated measures ANOVA).
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Figure 1. Effects of pulmonary rehabilitation on quality of life (St. 
George’s Respiratory Questionnaire, panel A) and exercise tolerance 
(6-min walking distance, panel B) in ex-smokers (Group I) and current 
smokers (Group II) with stable COPD. The box plots give the range, the 
central interquartile and the median. Note that both groups presented 
significant improvements after PR. However, the improvement in quality 
of life was greater in Group I (lower scores) compared to Group II.
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* p<0.05= post-PR within-group differences; † p<0.05= between-group differen-
ces in changes induced by PR (repeated measures ANOVA).
Subjective effects of PR on current smokers and 
ex-smokers 
According to Table 1, although both groups showed sig-
nificantly improved SGRQ scores19, this improvement was 
more pronounced in group II (Figure 1A). In fact, there was 
a decrease of more than four points in 15/16 (93.7%) group II 
participants and in 12/16 (75%) group I participants (p <0.05). 
In accordance with these findings, only group II showed a sig-
nificant reduction in the MRC dyspnea scores4.
The PR was associated with a significant reduction in the 
nicotine dependence scores in group II, and post-PR, 50% had 
mild dependence and 50%, moderate (p <0.05). Additionally, 
3/16 (18.7%) participants quit smoking. In accordance with 
these data, there was a significant decrease in the number of 
cigarettes per day (20±8 pre-PR vs. 7±6 post-PR; p <0.001). 
Objective effects of PR on current smokers and 
ex-smokers 
There was no significant change in BMI and lean mass in 
both groups, however, there was a significant reduction in the 
percentage of lean mass in group I (p <0.05; Table 1). As expec-
ted, the PR had no significant influence on the main spirome-
try variables in both groups. Interestingly, only group I showed 
significant improvement in MIP, while IC increased in group 
II (p <0.05; Table 1). With regard to functional exercise capa-
city (6MWD), the PR was associated with similar gains in both 
groups (Figure 1B, Table 1). Thus, individual analysis showed 
that a clinically significant gain (change in walking distance 
greater than 54 m)24 was found in 7/16 (43.7%) participants in 
group I and 9/16 (56.2%) in group II (p> 0.05). However, there 
was a significant reduction in symptoms of “leg effort” and 
“dyspnea” at the end of the test only in group I (Table 1). 
Discussion 
This study assessed the modulating effect of current 
smoking on adherence and the possible subjective and objec-
tive gains related to PR in participants with stable COPD. The 
results of this study indicate that, although current smoking 
was negatively related to adherence to PR, the clinical and 
physiological gains were generally similar in ex-smokers 
and current smokers (Table 1, Figure 1). In addition, the 
PR was associated with a significant reduction in nicotine 
dependence in current smokers. These results indicate that 
although a higher rate of withdrawal from PR can be antici-
pated in smokers with COPD, there seems to be no a priori 
clinical or physiological grounds to exclude such patients 
from PR programs. 
PR is currently considered a standard procedure for 
optimizing the clinical treatment of COPD patients with 
dyspnea and limitations in daily activities1,2,4,13,27. Although 
PR is considered useful for most patients in the moderate to 
advanced stages of the disease, the availability of such pro-
grams is limited, which stimulated the investigation of the 
most common limiting factors, especially current smoking. 
In this context, it should be recognized that smokers with 
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lung or heart disease known to be associated with smoking 
and who continue to smoke have lower adherence to drug 
treatment than those who quit28,29. 
Interestingly, such evidence has been extrapolated to 
non-pharmacological interventions, such as PR, without a 
clear experimental basis. In fact, previous studies considered 
the inclusion of smokers11,12,30,31. The negative and nihilistic 
psychological profile of many of these patients29 and its pos-
sible influence on adherence to the program and relapse of 
ex-smokers have been cited as possible deterrents to their 
inclusion in PR. Young et al.32, for example, reported that 
current smoking was associated with non-adherence to the 
PR. Our results are consistent with these findings because 
the risk of withdrawal was nearly three times that observed 
in current smokers compared to ex-smokers, i.e. a hazard 
ratio of 2.9. Thus, the inclusion of current smokers could be 
questionable, especially in countries with low availability of 
PR services, at least from the operational and cost minimiza-
tion point of view. 
A finding of great practical importance in the present 
study was the positive effect of PR on quitting smoking and 
the degree of nicotine dependence in group II. Obviously, 
although it is not possible to measure the relative impor-
tance of the different components of PR in this outcome, the 
anti-smoking educational activity, the information about the 
disease, the closer contact with the health team and reinfor-
cing example of ex-smokers may have been influential. Addi-
tionally, increased physical activity and better body care may 
also have contributed. These results are particularly notewor-
thy, considering that there was no systematic anti-smoking 
intervention in this study. 
PR programs have also had a significant effect on subjec-
tive improvement in patients with COPD33. Current smoking 
may, at least in theory, offset the positive impact of these 
post-PR gains33. Surprisingly, however, our data indicate the 
opposite, i.e. the current smokers not only improved in these 
aspects but they also exceeded the non-smokers (Table 1, Fi-
gure 1A). Although the tendency for greater dyspnea, poorer 
quality of life and higher baseline lung hyperinflation may 
have influenced these results (Table 1), our data combined 
with the improved nicotine dependence indicate that PR 
should not be discarded a priori for smokers with COPD, at 
least from a clinical point of view.
Another important aspect regarding the non-inclusion of 
smokers in PR is related to the lower potential for objective 
gains. Thus, the pro-inflammatory and systemic hyperoxi-
dative effects related to current smoking, the suppression of 
myogenic activity, the lower tolerance to heavy work loads and 
the accelerated loss of lung function could reduce functional 
gains in PR, as extensively reviewed by the American Thoracic 
Society and the European Respiratory Society34. In the present 
study, this hypothesis was not confirmed, and functional gains 
(6MWD) were similar in both groups. Additionally, there was a 
significant increase in IC in group II (Table 1). Nevertheless, this 
result should be viewed with extreme caution because there is 
no evidence that PR alone can reduce lung hyperinflation in 
COPD. Furthermore, the lower baseline IC values in group II 
may have induced the phenomenon of regression to the mean, 
i.e. the probability of increasing the scores in a re-assessment is 
inversely proportional to the pre-intervention values. 
The present study has some important limitations. Al-
though the sample size was suitable to demonstrate functional 
improvement with the 6MWD, the number of participants as-
sessed may have been insufficient to detect all possible factors 
related to non-adherence to PR. In this sense, the absence of 
psychosocial measures may also have been relevant. However, 
it should be noted that the number of assessed patients was 
higher than previously used in similar studies on adherence to 
PR17,18. Another important limitation is the non-inclusion of 
more complex measures of lung function, such as static lung 
volumes and diffusing capacity, thus not allowing a better 
phenotypic characterization of the participants35. Moreover, 
our results should not be extrapolated to patients with milder 
degrees of nicotine dependence or, in contrast, to more severe 
patients undergoing long-term oxygen therapy. Finally, there 
was no longitudinal follow-up of this sample, and the positive 
effects of long-term PR on reducing dependence and quitting 
smoking are not known. 
In conclusion, although current smoking in COPD patients 
reduces adherence to PR, smokers who complete the program 
have shown improvement in quality of life and functional exer-
cise capacity equivalent to that of ex-smokers. Even without a 
structured program for quitting smoking interruption, PR may 
be associated with short-term reduction in nicotine depen-
dence. Therefore, the decision to accept smokers with COPD 
into a PR program should be made in light of the local condi-
tions at each center, considering adverse economic factors and 
favorable clinical elements. 
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